MX2011007061A - Derivados de 2 piridin- 2-il-pirazol-3 (2h)-ona, su preparacion y aplicacion terapeutica. - Google Patents
Derivados de 2 piridin- 2-il-pirazol-3 (2h)-ona, su preparacion y aplicacion terapeutica.Info
- Publication number
- MX2011007061A MX2011007061A MX2011007061A MX2011007061A MX2011007061A MX 2011007061 A MX2011007061 A MX 2011007061A MX 2011007061 A MX2011007061 A MX 2011007061A MX 2011007061 A MX2011007061 A MX 2011007061A MX 2011007061 A MX2011007061 A MX 2011007061A
- Authority
- MX
- Mexico
- Prior art keywords
- group
- alkyl
- nr5r6
- aryl
- groups
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La inversión se refiere a los compuestos que responden a la formula (I), en estado de base o de sal por adicción de un acido: (I) en la cual n es igual a 0, 1, 2, 3 o 4; m es igual a 0, 1 o 2; o es igual a 0 o 1; X representa un grupo -CH2, -CH(R`)-,- NH(R`)- o un heteroátomo seleccionado entre O y S, entendiéndose que R` representa un grupo alquilo (C1_C5)alquilo, alcoxi (C1-C5), -CH2-arilo, -C(O)R5 o COOR5; R1 representa un grupo seleccionado entre los grupos (i) alquilo (C1-C5),(ii) alcoxi (C1-C5), (iii)- COOR5,(iv)- NR5R6, (v) -C(O)-NR5R6, (vi) -SO2 -NR3R4, (vii) heteroarilo eventualmente sustituido con un grupo alquilo (C1-C5), (viii)-W-arilo, (xi)-W-heteroarilo, (x) -O-W-arilo, (xi) -O-W-heteroarilo y (xii) -O-W- NR5R6; entendiendo que R3 y R4, (i) que pueden ser idénticos o diferentes, representa independientemente uno de otro, un átomo H, un grupo alqilo (C1-C5), cicloalquilo (C3-C6), arilo, heteroarilo, -CH2 -heteroarilo, alquil (C1-C5)-NR5R6,-W-OH o -W-NR5R6; o (ii) forman junto con el átomo de nitrógeno que los porta un grupo heterocicloalquilo eventualmente sustituido con uno o varios grupos seleccionados entre los grupos alquilo (C1-C5) y -CH2-arilo; w es un grupo alquileno-(C1-C5), eventualmente sustituido con uno o varios grupos hoidroxi; R5 y R6, que pueden ser idénticos o diferentes, representan, independendientemente uno de otro, un átomo de hidrogeno o un grupo seleccionado entre los grupos alquilo (C1-C5) y los grupos cicloalquilo (C3-C6), así como su procedimiento de preparación y sus aplicaciones en terapéutica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0807475A FR2940652B1 (fr) | 2008-12-29 | 2008-12-29 | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique |
FR0904091A FR2949468B1 (fr) | 2009-08-28 | 2009-08-28 | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique |
PCT/FR2009/052692 WO2010076525A1 (fr) | 2008-12-29 | 2009-12-24 | Dérivés de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur préparation et leur application en thérapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011007061A true MX2011007061A (es) | 2011-12-16 |
Family
ID=41728182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011007061A MX2011007061A (es) | 2008-12-29 | 2009-12-24 | Derivados de 2 piridin- 2-il-pirazol-3 (2h)-ona, su preparacion y aplicacion terapeutica. |
Country Status (34)
Country | Link |
---|---|
US (2) | US8697731B2 (es) |
EP (1) | EP2382215B1 (es) |
JP (1) | JP5865704B2 (es) |
KR (1) | KR101630475B1 (es) |
CN (1) | CN102333776B (es) |
AR (1) | AR074916A1 (es) |
AU (1) | AU2009334570B2 (es) |
BR (1) | BRPI0923875A2 (es) |
CA (1) | CA2748413A1 (es) |
CO (1) | CO6400145A2 (es) |
CR (1) | CR20110360A (es) |
CY (1) | CY1115635T1 (es) |
DK (1) | DK2382215T3 (es) |
EA (1) | EA019774B1 (es) |
EC (1) | ECSP11011164A (es) |
ES (1) | ES2511917T3 (es) |
HK (1) | HK1163679A1 (es) |
IL (1) | IL213790A (es) |
MA (1) | MA32978B1 (es) |
MX (1) | MX2011007061A (es) |
MY (1) | MY155244A (es) |
NI (1) | NI201100132A (es) |
NZ (1) | NZ593797A (es) |
PA (1) | PA8856101A1 (es) |
PE (1) | PE20120338A1 (es) |
PL (1) | PL2382215T3 (es) |
PT (1) | PT2382215E (es) |
SG (1) | SG172422A1 (es) |
SI (1) | SI2382215T1 (es) |
SM (1) | SMT201400157B (es) |
TN (1) | TN2011000308A1 (es) |
TW (1) | TWI441828B (es) |
WO (1) | WO2010076525A1 (es) |
ZA (1) | ZA201104785B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2382215T3 (pl) | 2008-12-29 | 2015-01-30 | Sanofi Sa | Pochodne 2-pirydyny-2-ylo-pirazol-3(2H)-onu, ich wytwarzanie i zastosowanie terapeutyczne |
EP2361912A1 (en) * | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
EP2361911A1 (en) * | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
EP2832733B1 (en) | 2012-03-30 | 2018-08-29 | Daiichi Sankyo Company, Limited | 4-alkanoylamino-3-pyrazolone derivative |
CN102731384B (zh) * | 2012-07-10 | 2016-04-06 | 南开大学 | 一种6-甲基烟酸叔丁酯的合成方法 |
CN105492433B (zh) | 2013-03-29 | 2018-11-23 | 武田药品工业株式会社 | 6-(5-羟基-1h-吡唑-1-基)烟碱酰胺衍生物和其作为phd抑制剂的用途 |
CN105061316B (zh) * | 2015-07-17 | 2017-12-22 | 苏州大学 | 稠环类化合物、制备方法和用途 |
CN113072562B (zh) * | 2021-04-06 | 2022-01-14 | 山东大学 | 一种GSK-3β抑制剂及其制备方法与应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3917469A1 (de) * | 1989-05-30 | 1990-12-06 | Bayer Ag | Heterocyclylpyridine |
DE4023488A1 (de) | 1990-07-24 | 1992-01-30 | Bayer Ag | 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide |
US5750088A (en) * | 1993-03-30 | 1998-05-12 | The Dupont Merck Pharmaceutical Company | Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals |
GB9704762D0 (en) | 1997-03-07 | 1997-04-23 | Zeneca Ltd | Chemical process |
CN1842332A (zh) * | 2003-06-30 | 2006-10-04 | Hif生物公司 | 化合物、组合物及方法 |
CA2530679A1 (en) * | 2003-06-30 | 2005-04-07 | Hif Bio, Inc. | Compounds for treating angiogenesis |
DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
AR059733A1 (es) | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
KR20090066297A (ko) * | 2006-10-16 | 2009-06-23 | 화이자 프로덕츠 인크. | 치료용 피라졸릴 티에노피리딘 |
DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
WO2008141731A2 (en) * | 2007-05-18 | 2008-11-27 | Bayer Healthcare Ag | Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
PL2382215T3 (pl) | 2008-12-29 | 2015-01-30 | Sanofi Sa | Pochodne 2-pirydyny-2-ylo-pirazol-3(2H)-onu, ich wytwarzanie i zastosowanie terapeutyczne |
MY179093A (en) | 2008-12-29 | 2020-10-27 | Sanofi Sa | Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof as hif activators |
-
2009
- 2009-12-24 PL PL09805790T patent/PL2382215T3/pl unknown
- 2009-12-24 CA CA2748413A patent/CA2748413A1/fr not_active Abandoned
- 2009-12-24 JP JP2011542887A patent/JP5865704B2/ja not_active Expired - Fee Related
- 2009-12-24 SG SG2011047529A patent/SG172422A1/en unknown
- 2009-12-24 PT PT98057904T patent/PT2382215E/pt unknown
- 2009-12-24 PE PE2011001291A patent/PE20120338A1/es not_active Application Discontinuation
- 2009-12-24 MX MX2011007061A patent/MX2011007061A/es active IP Right Grant
- 2009-12-24 BR BRPI0923875-1A patent/BRPI0923875A2/pt not_active IP Right Cessation
- 2009-12-24 DK DK09805790.4T patent/DK2382215T3/da active
- 2009-12-24 KR KR1020117017677A patent/KR101630475B1/ko active IP Right Grant
- 2009-12-24 EA EA201170900A patent/EA019774B1/ru not_active IP Right Cessation
- 2009-12-24 MY MYPI2011003011A patent/MY155244A/en unknown
- 2009-12-24 CN CN200980157589.3A patent/CN102333776B/zh not_active Expired - Fee Related
- 2009-12-24 SI SI200931025T patent/SI2382215T1/sl unknown
- 2009-12-24 MA MA34029A patent/MA32978B1/fr unknown
- 2009-12-24 NZ NZ593797A patent/NZ593797A/xx not_active IP Right Cessation
- 2009-12-24 ES ES09805790.4T patent/ES2511917T3/es active Active
- 2009-12-24 WO PCT/FR2009/052692 patent/WO2010076525A1/fr active Application Filing
- 2009-12-24 AU AU2009334570A patent/AU2009334570B2/en not_active Ceased
- 2009-12-24 EP EP09805790.4A patent/EP2382215B1/fr active Active
- 2009-12-28 AR ARP090105127A patent/AR074916A1/es unknown
- 2009-12-28 TW TW098145333A patent/TWI441828B/zh not_active IP Right Cessation
- 2009-12-28 PA PA20098856101A patent/PA8856101A1/es unknown
-
2011
- 2011-06-17 TN TN2011000308A patent/TN2011000308A1/fr unknown
- 2011-06-23 CR CR20110360A patent/CR20110360A/es unknown
- 2011-06-27 EC EC2011011164A patent/ECSP11011164A/es unknown
- 2011-06-27 IL IL213790A patent/IL213790A/en not_active IP Right Cessation
- 2011-06-28 NI NI201100132A patent/NI201100132A/es unknown
- 2011-06-28 ZA ZA2011/04785A patent/ZA201104785B/en unknown
- 2011-06-29 US US13/172,321 patent/US8697731B2/en not_active Expired - Fee Related
- 2011-06-29 CO CO11081313A patent/CO6400145A2/es active IP Right Grant
-
2012
- 2012-05-02 HK HK12104300.3A patent/HK1163679A1/xx not_active IP Right Cessation
-
2014
- 2014-03-07 US US14/200,698 patent/US9359329B2/en not_active Expired - Fee Related
- 2014-10-16 CY CY20141100849T patent/CY1115635T1/el unknown
- 2014-10-29 SM SM201400157T patent/SMT201400157B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011007061A (es) | Derivados de 2 piridin- 2-il-pirazol-3 (2h)-ona, su preparacion y aplicacion terapeutica. | |
MX2010013275A (es) | Compuesto novedoso de uracilo o su sal que tiene actividad inhibidora de desoxiuridin trifosfatasa de humano. | |
TW200604175A (en) | Ortho substituted aryl or heteroaryl amide compounds | |
MY142807A (en) | Benzimidazole derivative and use thereof. | |
MX2010003445A (es) | Derivados de nicotinamida, su preparacion y su uso terapeutico. | |
TW200745034A (en) | New compounds | |
MXPA06010097A (es) | Inhibidores de dipeptidil peptidasa-iv. | |
EA200601847A1 (ru) | Замещённые метиларил- или гетероариламидные соединения | |
UA101482C2 (ru) | Способ получения 2'-дезокси-5-азацитидина (децитабина) | |
DE60301345D1 (de) | Stabilisierte askorbinsäurederivate | |
NO20073787L (no) | Nye pyrimidin-nukleosidforbindelser eller dets salt | |
EA014959B3 (ru) | Ингибиторы глицинового переносчика-1 | |
MX2007007446A (es) | Procesos para la produccion de 4-aminoquinazolinas. | |
GEP20074256B (en) | Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing | |
MY161992A (en) | Novel tetrahydroisoquinoline derivative | |
ATE489367T1 (de) | Verfahren und zwischenprodukt zur herstellung von donezepil | |
TW200619201A (en) | Process for the preparation of pyrazoles | |
TW200738681A (en) | Isoquinoline and benzo[h]isoquinoline derivatives, their preparation and their use in therapeutics | |
PL1819704T3 (pl) | Amidowe pochodne kwasu pirolopirydyno-2-karboksylowego użyteczne jako inhibitory fosforylazy glikogenowej | |
TNSN06337A1 (en) | 6-substituted pyridoindolone derivatives production and therapeutic use thereof | |
TW200716112A (en) | Benzimidazole compound | |
RS20060157A (en) | Method for the manufacture of thip | |
ATE471333T1 (de) | Neue zuckerderivate, verfahren für ihre zubereitung und ihre verwendung als oberflächenaktive mittel | |
EA200500716A1 (ru) | Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат | |
DE602004020050D1 (de) | Verfahren zur herstellung substituierter imidazolderivate und in dem verfahren verwendete zwischenprodukte |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |